Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Bad
|
New words:
ADC, adenosine, Alector, amplification, atopic, auditor, bone, cGVHD, concept, consummation, creation, cytarabine, depatuxizumab, DMT, doubtful, EGFR, eleven, endpoint, exploratory, fewer, Fremont, GBM, GmbH, graft, host, IMMhance, intolerant, justify, Kabi, LDAC, lomustine, mafodotin, marrow, MAVIRET, MAVYRET, MURANO, negligence, neurodegenerative, Nutrition, OS, PARP, PCAOB, pibrentasvir, platinum, poly, polymerase, Postretirement, preliminarily, prolonged, pronouncement, proof, recurrent, revealed, Rituxan, Robert, Rubinstein, SLL, SONAR, temozolomide, TMZ, TNBC, topotecan, untaxed, upadacitinib, ustekinumab, vacated, wholly, WM
Removed:
Ablynx, affirmed, allocated, announcement, attaining, basic, Biogen, BMS, break, closing, comprised, concerted, declined, dedicate, distributed, duvelisib, elotuzumab, equitable, Euronext, exclusively, exit, favor, finite, footage, franchise, GlaxoSmithKline, headcount, healthcare, hematologic, Hillman, Hurwich, hypothetical, identifying, improper, inflow, Influenced, jointly, juror, lipid, methodology, Moody, mutually, myeloma, Nanobody, Neurocrine, neurodegeneration, NV, opted, outlook, partnering, Racketeer, rata, RBV, recently, recommended, remanded, repatriate, replaced, returned, reversed, Rochester, seasonal, shared, SICAD, square, Squibb, stable, supporting, suppurativa, terminate, ulcerative, undesignated, usage, withdrew
Filing tables
Filing exhibits
Related press release
Associated ABBV transcripts
ABBV similar filings
Filing view
External links
Exhibit 12.2
AbbVie Inc.
Computation of Ratio of Earnings to Fixed Charges
(unaudited)
(in millions, except for ratio) | Year ended December 31, 2017 | Year ended December 31, 2016 | Year ended December 31, 2015 | ||||||||||
Determination of earnings: | |||||||||||||
Earnings before income tax | $ | 7,727 | $ | 7,884 | $ | 6,645 | |||||||
Add (deduct): | |||||||||||||
Fixed charges | 1,222 | 1,222 | 923 | ||||||||||
Interest capitalized during period (a) | (5 | ) | (112 | ) | (143 | ) | |||||||
Total earnings as defined | $ | 8,944 | $ | 8,994 | $ | 7,425 | |||||||
Fixed charges: | |||||||||||||
Interest expense | $ | 1,150 | $ | 1,155 | $ | 860 | |||||||
Capitalized interest | 16 | 14 | 14 | ||||||||||
Rent expense (b) | 56 | 53 | 49 | ||||||||||
Total fixed charges | $ | 1,222 | $ | 1,222 | $ | 923 | |||||||
Ratio of earnings to fixed charges | 7.3 | 7.4 | 8.0 |
(a) Interest capitalized during the period is deducted because fixed charges include all interest, whether capitalized or expensed. Only fixed charges that were deducted from income were included in the earnings computation.
(b) AbbVie considers one-third of rent expense to be a reasonable approximation of the interest factor in its leases.